Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, celebrated the receipt of its 24th granted patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” Granted in Australia, this is the first patent awarded from the company’s 8th patent family. “The new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills. It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine and other nicotine complexes,” reads a recent article. Prior to the award of the 24th patent, Lexaria already had a patent granted in Australia to use DehydraTECH-processed cannabidiol (“CBD”) to potentially treat heart disease. “Thus, the new Australian patent covering the use of DehydraTECH-nicotine builds on the existing IP protection there and sets the stage for the company to exploit nicotine- and CBD-oriented opportunities within this market.”
To view the full article, visit https://ibn.fm/s8GK1
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.